Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-7117 PK in Renal Impairment
NCT04656795Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dersimelagon in erythropoietic protoporphyria (EPP) (4 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration time curve from time zero to the last quantifiable concentration and 1 more. Started Dec 2020; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT04656795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656795.